Gene therapy for treating SPG50 in children

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

MELPIDA is a gene therapy designed to treat Spastic Paraplegia Type 50 (SPG50) by delivering a functional copy of the human AP4M1 gene directly to neuronal cells through intrathecal injection. This Phase 1/2 trial aims to evaluate the safety and tolerability of a single dose of MELPIDA, while also assessing its efficacy in reducing disease burden. The study focuses on children aged 4 months to 10 years who have a confirmed diagnosis of SPG50, characterized by progressive neurodegeneration and associated symptoms. The trial will monitor treatment-related adverse events and serious adverse events as primary outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 4 months-10 years old
2. Confirmed diagnosis of SPG50 disease by:

   1. Genomic DNA mutation analysis demonstrating homozygous or compound heterozygous, confirmed pathogenic variants in the AP4M1 gene
   2. Clinical history or examination features consistent with SPG50 and that include neurologic dysfunction
3. Parent/legal guardian willing to provide written informed consent for their child prior to participation in the study
4. Subject able to comply with all protocol requirements and procedures
5. Ability to stand for more than 5 seconds OR
6. Ability to take 5 steps independently or with a walker OR
7. Modified Ashworth Scale score 2 or below (Ankles).

Exclusion Criteria:

1. Inability to participate in study procedures (as determined by the site investigator)
2. Presence of a concomitant medical condition that precludes lumbar puncture (LP) or use of anesthetics
3. History of bleeding disorder or any other medical condition or circumstance in which lumbar puncture is contraindicated according to local institutional policy
4. Inability to be safely sedated in the opinion of the clinical anesthesiologist
5. Active infection, at the time of dosing, based on clinical observations
6. Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer
7. Inability of the patient to undergo MRI according to local institutional policy
8. Inability of the patient to undergo any other procedure required in this study
9. The presence of significant non-SPG50 related CNS impairment or behavioral disturbances that would confound the scientific rigor or interpretation of results of the study
10. Have received an investigational drug within 30 days prior to screening or plan to receive an investigational drug (other than gene therapy) during the study.
11. Enrollment and participation in another interventional clinical trial
12. Contraindication to MELPIDA or any of its ingredients
13. Contraindication to any of the immune suppression medications used in this study
14. Clinically significant abnormal laboratory values (GGT, ALT, and AST, or total bilirubin \> 3 × ULN, creatinine ≥ 1.5 mg/dL, hemoglobin \[Hgb\] \< 6 or \> 20 g/dL; white blood cell \[WBC\] \> 20,000 per cmm) prior to gene replacement therapy.

Where it's running

• Children's Medical Center Dallas
  Dallas, Texas, United States Recruiting

Study contacts

• Principal investigator: Susan T. Iannaccone, MD, FAAN — University of Texas Southwestern Medical Center
• Study coordinator: Elaine Most, MS
• Email: elaine.most@utsouthwestern.edu
• Phone: 214-456-2463

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Palpatory vs ultrasound-guided botulinum toxin injections for spastic paraplegia

  This study tests whether ultrasound-guided injections of botulinum toxin improve outcomes for adults with spastic paraplegia compared with the traditional palpation-guided method.

  Recruiting Phase 4 Universidade Federal Fluminense · Rio de Janeiro, Rio de Janeiro · NCT07803276

• Brain–spinal cord–muscle connectivity during selective dorsal rhizotomy in children with spasticity

  This project will record brain-to-spinal-cord-to-muscle signals during selective dorsal rhizotomy in children ages 3–17 with spasticity to see how the surgery changes nervous system connections.

  Recruiting at 2 sites Fondation Ophtalmologique Adolphe de Rothschild · Nice and 1 other locations · NCT06281223

• Measuring lower extremity activity in stroke patients

  This study is testing a new questionnaire to see how well stroke patients use their affected legs in daily activities to better understand their rehabilitation needs.

  Recruiting Gaziantep Islam Science and Technology University · Gaziantep · NCT06156813

• Effectiveness of the Mollii Suit for children with cerebral palsy

  This study is testing if the Mollii Suit can help children with spastic cerebral palsy improve their movement and reduce pain.

  Recruiting Kastamonu University · Ankara · NCT06109129

• Treatment for muscle tightness after stroke, spinal cord injury, or cerebral palsy

  This study is testing a new treatment using targeted radiation to see if it can help reduce muscle tightness in people who have had a stroke, spinal cord injury, or have cerebral palsy.

  Recruiting at 2 sites Ohio State University · Winter Park, Florida and 1 other locations · NCT06070233

• Observational study on MEHMO syndrome and related conditions

  This study follows people with MEHMO syndrome and related disorders to see how the conditions develop over time and to find better ways to diagnose and manage them.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06019182

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.